Rapamycin has dual opposing effects on proteinuric experimental nephropathies: Is it a matter of podocyte damage

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3632-3640

  Torras, Juan ^a   Herrero Fresneda, Immaculada ^a   Gulias, Oscar ^a   Flaquer, Maria ^a   Vidal, August ^a   Cruzado, Josep M ^a   Lloberas, Nuria ^a   Franquesa, Marcella ^a   Grinyó, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Proteinuria; Puromycin aminonucleoside nephropathy; Rapamycin; Renal mass reduction

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NEPHRIN; PODOCIN; PROTEIN KINASE B; PUROMYCIN AMINONUCLEOSIDE; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DRUG MEGADOSE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; KIDNEY DISEASE; KIDNEY HYPERTROPHY; KIDNEY INJURY; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; ULTRAFILTRATION;

ANIMALS; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROSIS, LIPOID; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS;

EID: 71049162614     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp367     Document Type: Article

References (44)

1. Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6: 1991-1998
2. Halloran PH. Immunosuppressive drugs for kidney transplantation N Engl J Med 2004; 351: 2715-2729
3. Stallone G, Di Paolo S, Schena A et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228-233
4. Crew RJ, Radhakrishnan J, Cohen DJ et al. De novo thrombotic microangiopathy following treatment with sirolimus: Report of two cases. Nephrol Dial Transplant 2005; 20: 203-209
5. Straathof-Galema L, Wetzels JF, Dijkman HB et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006; 6: 429-433
6. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326-333
7. Lloberas N, Cruzado JM, Franquesa M et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404
8. Bonegio RG, Fuhro R, Wang Z et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-2072
9. Bumbea V, Kamar N, Ribes D et al. Long-term results in renal transplant patients with allograft dysfunction after switching from cal-cineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517-2523
10. Daniels BS, Deen WM, Mayer G et al. Glomerular permeability barrier in the rat. Functional assessment by in vitro methods. J Clin Invest 1993; 92: 929-993
11. Ruotsalainen V, Ljungberg P, Wartiovaara J et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 1999; 96: 7962-7967
12. Ruotsalainen V, Patrakka J, Tissari P et al. Role of nephrin in cell junction formation in human nephrogenesis. Am J Pathol 2000; 157: 1905-1916
13. Huber TB, Kottgen M, Schilling B et al. Interaction with podocin facilitates nephrin signaling. J Biol Chem 2001; 276: 41543-41546
14. Salant D, Cybulsky A. Experimental glomerulonephritis. Meth Enzy-mol 1988; 162: 421-461
15. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev 1979; 59: 137-164
16. Franquesa M, Alperovich G, Herrero-Fresneda I et al. Direct electro-transfer of hHGF gene into kidney ameliorates ischemic acute renal failure. Gene Ther 2005; 12: 1551-1558
17. Guan N, Ding J, Deng J et al. Key molecular events in puromycin aminonucleoside nephrosis rats. Pathol Int 2004; 54: 703-711
18. Herrero-Fresneda I, Torras J, Cruzado JM et al. Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy? Am J Pathol 2003; 162: 127-137
19. Rincon J, Romero M, Viera N et al. Increased oxidative stress and apoptosis in acute puromycin aminonucleoside nephrosis. Int J Exp Pa t h 2004; 85: 25-33
20. Hosoyamada M, Yan K, Nishibori Y et al. Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis. J Pharmacol Sci 2005; 97: 234-241
21. Peraldi MN, Morelon E, Mamzer-Brunel MF et al. Renal function and pathology after switch from calcineurin-dependent drugs to sirolimus in renal transplant recipients with chronic graft nephropathy [abstract A3694]. J Am Soc Nephrol 2000; 11: 702A
22. Daniel C, Renders L, Amann K et al. Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant 2005; 5: 2849-2861
23. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular en-dothelial growth (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017
24. Diekmann F, Rovira J, Carreras J et al. Mammalian target of ra-pamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007; 18: 2653-2660
25. Vogelbacher R, Wittmann S, Braun A et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492-1499
26. Liu G, Kaw B, Kurfis J et al. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest 2003; 112: 209-221
27. Zhu J, Sun N, Aoudjit L et al. Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. Kidney Int 2008; 73: 524-526
28. Hostetter TH, Olson JL, Rennke HG et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol 2001; 12: 1315-1325
29. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J et al. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 2004; 286: F606-F616
30. Chow F, Ozols E, Nikolic-Paterson DJ et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004; 65: 116-128
31. Fujihara CK, Antunes GR, Mattar AL et al. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int 2003; 64: 2172-2181
32. Anders HJ, Ninichuk V, Schlondorff D. Progression of kidney disease: blocking leukocyte recruitment with chemokine receptor CCR1 antagonists. Kidney Int 2006; 69: 29-32
33. Herrero-Fresneda I, Torras J, Vidal A et al. Reduction of postischemic immune inflammatory response: an effective strategy for attenuating chronic allograft nephropathy. Transplantation 2005; 79: 165-173
34. Fornoni A, Ijaz A, Tejada T et al. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 2008; 4: 10-17
35. Rastaldi MP. Epithelial-mesenchymal transition and its implications for the development of renal tubulointerstitial fibrosis. J Nephrol 2006; 19: 407-412
36. Herrero-Fresneda I, Torras J, Franquesa M et al. HGF gene therapy attenuates renal allograft scarring by preventing the profi-brotic inflammatory-induced mechanisms. Kidney Int 2006; 70: 265-274
37. Wu MJ, Wen M, Chiu Y et al. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006; 69: 2029-2036
38. Jain S, Bicknell GR, Whiting PHet al.Sirolimus reduces expression of fibrosis-associated genes in an experimental model of renal ischemia reperfusion injury. Transplant Proc 2001; 33: 556-558
39. Kim YH, Goyal M, Kurnit D et al. Podocyte depletion and glomeru-losclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60: 957-968
40. Coombes JD, Mreich E, Liddle Cet al.Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 2005; 68: 2599-2607
41. Yang X, Shen Y, Zhu Z et al. Apoptosis signaling pathway in a subtotal nephrectomy rat model. J Huazhong Univ Sci Technolog Med Sci 2006; 26: 425-428
42. Nagai K, Matsubara T, Mima A et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int 2005; 68: 552-561
43. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101
44. Zeng Z, Sarbassov dos D, Samudio IJ et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509-3512